Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Systemic adverse events following rituximab therapy in patients with Graves' disease

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{e7d0023c9cb347b2b2b3188b63c9d053,
title = "Systemic adverse events following rituximab therapy in patients with Graves' disease",
abstract = "Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.",
author = "{El Fassi}, D and Nielsen, {Claus Henrik} and Junker, {Michael Peter} and Hasselbalch, {H C} and L Heged{\"u}s",
year = "2011",
doi = "10.3275/7411",
language = "English",
volume = "34",
pages = "e163--7",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice/Kurtis s.r.l",
number = "7",

}

RIS

TY - JOUR

T1 - Systemic adverse events following rituximab therapy in patients with Graves' disease

AU - El Fassi, D

AU - Nielsen, Claus Henrik

AU - Junker, Michael Peter

AU - Hasselbalch, H C

AU - Hegedüs, L

PY - 2011

Y1 - 2011

N2 - Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.

AB - Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.

U2 - 10.3275/7411

DO - 10.3275/7411

M3 - Journal article

VL - 34

SP - e163-7

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 7

ER -

ID: 32712566